Drugs Made In America Acquisition Corp. (DMAAR) Non-Current Debt (2024 - 2025)

Drugs Made In America Acquisition (DMAAR) has reported Non-Current Debt for 2 consecutive years, with $60898.0 the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Non-Current Debt changed N/A year-over-year to $60898.0; the trailing twelve-month figure through Mar 2025 stood at $60898.0 (changed N/A YoY), and the FY2024 full-year result was $662324.0, changed N/A from the prior year.
• Non-Current Debt slipped to $60898.0 in Q1 2025 per DMAAR's latest filing, from $662324.0 in the prior quarter.
• Across five years, Non-Current Debt topped out at $662324.0 in Q4 2024 and bottomed at $60898.0 in Q1 2025.